Point72 Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Point72 Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$329K	Buy	+154,408	New	+$265K	﹤0.01%	3348
2026 Q1	–	Sell	-94,094	Closed	-$487K	–	3737
2025 Q4	$487K	Buy	+94,094	New	+$483K	﹤0.01%	3241
2023 Q2	–	Sell	-8,510	Closed	-$84.5K	–	2124
2023 Q1	$84.5K	Buy	+8,510	New	+$60.2K	﹤0.01%	1668
2021 Q1	–	Sell	-858,270	Closed	-$5.89M	–	935
2020 Q4	$5.89M	Buy	858,270 +216,352	+34%	+$1.52M	0.03%	552
2020 Q3	$4.76M	Buy	+641,918	New	+$4.15M	0.02%	576
2019 Q3	–	Sell	-325,000	Closed	-$1.95M	–	1105
2019 Q2	$1.95M	Buy	+325,000	New	+$2.45M	0.01%	656

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Point72 Asset Management's ALDX Position: Q2 2026 in Review

Point72 Asset Management opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2026: 154,408 shares worth $329K. The stake represents ﹤0.01% of the portfolio and ranks #3348 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in ALDX as recently as Q4 2025.

Point72 Asset Management first reported a position in ALDX in Q2 2019 and has held it in 6 quarters since. The position peaked at $5.89M in Q4 2020. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Point72 Asset Management held 154,408 shares of Aldeyra Therapeutics worth $329K as of Q2 2026.
Aldeyra Therapeutics was a new Point72 Asset Management position in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3348 holding.
Point72 Asset Management first reported a position in Aldeyra Therapeutics in Q2 2019 and has held it in 6 quarters since.
Point72 Asset Management's Aldeyra Therapeutics position peaked at $5.89M in Q4 2020.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.